Advertisement
News
Subscribe to MDT Magazine News

VC-backed Vedanta to target cancer via 'good' bacteria

December 23, 2010 10:33 am | by Mass High Tech: The Journal of New England Technology | Comments

Venture capital firm PureTech Ventures is launching a new company, called Vedanta Biosciences, to commercialize research newly published today in the academic journal Science that indicates beneficial, gut-dwelling bacteria may also be useful for combating allergies and inflammatory bowel disease.

Made in IBM Labs: Scientific Discovery Moves Racetrack Memory Closer to Reality

December 23, 2010 10:32 am | by IBM | Comments

IBM Researchers today revealed a previously unknown aspect of key physics inside Racetrack memory -- a new technology design which stands to improve memory capabilities within mobile phones, laptop computers and business-class servers. This new class of memory could enable devices to...

Biogen Idec, Elan apply for MS drug label update

December 23, 2010 9:38 am | by Mass High Tech: The Journal of New England Technology | Comments

Biogen Idec Inc. and Elan Corp. plc, the co-owners of multiple sclerosis drug Tysabri, have sent a recommendation to the U.S. Food and Drug Administration and the European Medicines Agency to update the labeling of the drug in order to clarify the risk of a rare but potentially fatal...

TOPICS:
Advertisement

ACT seeks orphan drug status in Europe for vision loss treatment

December 23, 2010 9:37 am | by Mass High Tech: The Journal of New England Technology | Comments

Advanced Cell Technology Inc. has filed in Europe for Orphan Drug Designation for its retinal epithelial (RPE) cells to treat Stargardt's Macular Dystrophy (Stargardt's Disease), according to a news release today.

Pathfinder, SyntheMed merge

December 23, 2010 9:37 am | by Mass High Tech: The Journal of New England Technology | Comments

Pathfinder LLC, a private Cambridge cell-based therapeutics firm, and New Jersey biomaterials firm SyntheMed Inc. have merged, the two companies announced Wednesday. The newly formed company will be called Pathfinder Cell Therapy Inc. and have its headquarters in Cambridge.

Significant improvement in LED fundamental and manufacturing technologies needed for massive adoption in general lighting applications

December 23, 2010 7:32 am | by I-Micronews | Comments

Yole Développement (Lyon, France) and EPIC (Paris, France) announce the publication of their new market & technological study dedicated to LED industry: LED ManTech Report.

New CVS Caremark Study Finds Health Information Technology May Help Promote Adherence, But More Information and Direction Needed

December 23, 2010 7:31 am | by Bio-Medicine.Org | Comments

WOONSOCKET, R.I., Dec. 23, 2010 /- A new study that reviews more than four decades of medical journal articles about the impact of health information technology (HIT) and electronic communications on medication adherence concludes that while there is evidence to suggest that simple...

TOPICS:

Cannabis Science Forms Military Advisory Board That Will Be Comprised of Distinguished Military Leaders, Military Health Care Providers, Researchers and Educators Headed Up by...

December 23, 2010 7:31 am | by Bio-Medicine.Org | Comments

COLORADO SPRINGS, Colo., Dec. 23, 2010 /- Cannabis Science, Inc. (OTC Bulletin Board: CBIS ), a pioneering U.S. biotech company developing pharmaceutical cannabis products, announced today that it has formed a Military Advisory Board, that will be comprised of distinguished military...

TOPICS:
Advertisement

BioRelix lands $2.4M financing

December 23, 2010 6:33 am | by Mass High Tech: The Journal of New England Technology | Comments

BioRelix Inc., a New Haven, Conn.-based biotech focused on developing infectious disease treatments, has taken in $2.4 million of a planned $4.8 million debt and warrants financing, according to a regulatory filing.

Fruta Planta: Public Notification - Undeclared Drug Ingredient

December 23, 2010 6:31 am | by U.S. Food & Drug Administration | Comments

Product marketed as a dietary supplement contains sibutramine, a controlled substance known to substantially increase blood pressure and/or pulse rate, and may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias or stroke.

TOPICS:

RockHard Weekend, Pandora: Recall - Undeclared Drug Ingredient

December 23, 2010 6:30 am | by U.S. Food & Drug Administration | Comments

Product marketed as dietary supplement contains undeclared analogue of sildenafil, a drug which may interact with nitrates found in some prescription drugs and lower blood pressure to dangerous levels.

TOPICS:

Cephalon names J. Kevin Buchi CEO

December 23, 2010 4:45 am | by The Associated Press | Comments

Cephalon Inc. on Thursday named J. Kevin Buchi as CEO and a member of the company's board of directors, making his temporary responsibilities at the biotechnology company permanent.Buchi, the company's chief operating officer, had taken over the CEO responsibilities in August after Frank...

SU scientists find that in the evolutionary mating game, brawn and stealth rule

December 23, 2010 4:37 am | by EurekAlert | Comments

(Syracuse University) When prowling for a hook up, it's not always the good-looker who gets the girl. In fact, in a certain species of South American fish, brawn and stealth beat out colorful and refined almost every time.

TOPICS:

MiMedx Receives Additional CE Certification for Its HydroFixâ„¢ Technology

December 23, 2010 4:35 am | by Bio-Medicine.Org | Comments

MARIETTA, Ga., Dec. 23, 2010 /- MiMedx Group, Inc. (OTC Bulletin Board: MDXG ), an integrated developer, manufacturer and marketer of patent protected biomaterial-based products, announced today that it has received notification of the Class III certification for a European product using...

TOPICS:

Masimo to Present at 29th Annual J.P. Morgan Healthcare Conference

December 23, 2010 4:33 am | by Bio-Medicine.Org | Comments

IRVINE, Calif., Dec. 23, 2010 /PRNewswire / -- Masimo (Nasdaq: MASI ) today announced that its management is scheduled to present at the 29th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Tuesday, January 11, 2011, at 11:30 a.m. PT.  A...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading